Literature DB >> 2425100

Successful treatment of renal vein and vena caval extension of nephroblastoma by preoperative chemotherapy.

S J Kogan, H Marans, M Santorineau, K Schneider, E Reda, S B Levitt.   

Abstract

Intravascular nephroblastoma involving the renal veins or inferior vena cava, occurring in 6 to 10 per cent of the cases, dramatically complicates the treatment course for those individuals. Heroic surgical procedures, including sternal splitting and cardiopulmonary bypass, have been used to treat these tumors, often with an added morbidity and increased mortality. We have detailed the dramatic responses to preoperative chemotherapy in 3 patients with intravascular nephroblastoma, which resulted in either complete eradication or marked shrinkage of the intravascular tumor, greatly simplifying the ensuing surgical procedure. These observations strongly indicate that preoperative chemotherapy should be used as the primary treatment in patients with this condition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425100     DOI: 10.1016/s0022-5347(17)44852-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Successful treatment of intracaval and atrial extension of Wilms' tumour by chemotherapy.

Authors:  S Berberoğlu; C Akyüz; M Büyükpamukçu
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

2.  Intravascular extension of Wilms tumor.

Authors:  R C Shamberger; M L Ritchey; G M Haase; T L Bergemann; T Loechelt-Yoshioka; N E Breslow; D M Green
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

3.  Clinico-immunological response to intratumoral versus intravenous neoadjuvant chemotherapy in advanced pediatric solid malignancies.

Authors:  Vijayendra Kumar; Nandini Ramaswami; Anand Pandey; Ram Chandra Shukla; Maloy Ranjan Sen; Shiv Prasad Sharma; Dinesh Kumar Gupta; Ajay Narayan Gangopadhyay
Journal:  Indian J Med Paediatr Oncol       Date:  2013-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.